Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Mehr anzeigen
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The...
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided...
BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -6.21118012422 | 1.61 | 1.61 | 1.45 | 135622 | 1.55993401 | CS |
| 4 | -0.09 | -5.625 | 1.6 | 1.94 | 1.45 | 503647 | 1.63642489 | CS |
| 12 | -0.16 | -9.58083832335 | 1.67 | 1.94 | 1.45 | 209474 | 1.65248526 | CS |
| 26 | -0.23 | -13.2183908046 | 1.74 | 1.94 | 1.45 | 125932 | 1.66460764 | CS |
| 52 | -0.31 | -17.032967033 | 1.82 | 1.94 | 1.22 | 238813 | 1.53105823 | CS |
| 156 | -9.75 | -86.5896980462 | 11.26 | 11.79 | 1.02 | 170299 | 3.07586083 | CS |
| 260 | -20.89 | -93.2589285714 | 22.4 | 37.61 | 1.02 | 167897 | 5.73011284 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
